Experimental HIV Drugs
Experimental HIV Drugs
FDA Approves Gilead's Genvoya Single-tablet Regimen with Tenofovir Alafenamide
- Details
- Category: Experimental HIV Drugs
- Published on Thursday, 05 November 2015 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration (FDA) announced on November 5 the approval of Gilead Sciences' Genvoya, a new once-daily single-tablet regimen containing the integrase inhibitor elvitegravir, the booster cobicistat, emtricitabine, and tenofovir alafenamide (TAF) -- a new formulation that is easier on the kidneys and bones than the older tenofovir disoproxil fumarate (TDF).
Long-acting Injectable Cabotegravir + Rilpivirine Maintains HIV Suppression for 32 Weeks
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 03 November 2015 00:00
- Written by Liz Highleyman
A combination of 2 long-acting injectable antiretrovirals -- ViiV Healthcare's experimental integrase inhibitor cabotegravir and Janssen's NNRTI rilpivirine -- given once every 4 or 8 weeks maintained viral suppression as well as a standard oral regimen and appears safe and well-tolerated, the companies announced this week. These findings from the Phase 2b LATTE 2 trial follow earlier reports from the original LATTE study showing that oral cabotegravir plus rilpivirine suppressed HIV as well as an efavirenz-based regimen, but with fewer side effects.
EACS 2015: TAF Single-Tablet Regimen Shows Good Efficacy, Improved Kidney and Bone Safety
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 23 October 2015 00:00
- Written by Liz Highleyman
A single-tablet regimen containing the new tenofovir alafenamide (TAF) -- to be marketed as Genvoya -- suppressed HIV as well as a coformulation containing the older tenofovir disoproxil fumarate (TDF), according to a poster presented this week at the 15th European AIDS Conference in Barcelona. A related studyfound that people who switched from an atazanavir (Reyataz)-based regimen to the new combo had superior virological outcomes, and in both clinical trialsparticipants saw improvements in kidney and bone biomarkers.
EACS 2015: HIV Maturation Inhibitor BMS-955176 Shows Good Safety and Efficacy in Phase 2a Trial
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 27 October 2015 00:00
- Written by Liz Highleyman
Bristol-Myers Squibb's next-generation maturation inhibitor BMS-955176 demonstrated good antiviral activity against HIV subtypes B and C in a short proof-of-concept study, and appeared to be safe and well-tolerated, according to findings presented last week at the 15th European AIDS Conference in Barcelona.
IDWeek 2015: Studies Continue to Support Tenofovir Alafenamide as it Nears Approval
- Details
- Category: Experimental HIV Drugs
- Published on Wednesday, 14 October 2015 00:00
- Written by Liz Highleyman
A single-tablet regimen containing a new formulation of tenofovir maintained viral suppression when switching from other combinations and was associated with improved kidney function and bone health, according to studies presented at IDWeek 2105 last week in San Diego. Other research showed that the new formulation works better than the old one for black patients and for older people, and that it can be safely used with sofosbuvir/ledipasvir (Harvoni) for hepatitis C treatment.
More Articles...
- IDWeek 2015: HIV Attachment Inhibitor BMS-663068 Matches Atazanavir in Phase 2b Study
- Coverage of 2015 Interscience Conference on Antimicrobial Agents and Chemotherapy
- Tenofovir Alafenamide Combo Pill Matches Truvada for HIV Efficacy, but Easier on Bones and Kidneys
- IAS 2015: Switching to Tenofovir Alafenamide Keeps HIV Suppressed, Helps Kidneys and Bones
Web Design and Development by